Friday, July 10, 2026
🇺🇸 FDA

pharma · Early Childhood Caries · Acute Myeloid Leukemia

University of Hong

The University of Hong Kong

University of Hong drug portfolio — 71 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
42
Drugs
71
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

University of Hong pipeline

Portfolio lens on 71 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

University of Hong drug portfolio — 71 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

71 compounds

  1. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  2. alcohol

    US regulatory status: approved.

  3. amlodipine

    Cardiovascular system (C09)

    Cardiovascular system (C09) compound in University of Hong's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.

    Mechanism
    Voltage-gated L-type calcium channel blocker

  6. amlodipine besilate

    Cardiovascular system (C09)

    Cardiovascular system (C09) compound in University of Hong's portfolio. Molecular target: Voltage-gated L-type calcium channel.

    Target
    Voltage-gated L-type calcium channel
    Mechanism
    Voltage-gated L-type calcium channel blocker

  7. anesthesia

    Development asset linked to University of Hong in public FDA and regional records.

  8. arsenic

    Development asset linked to University of Hong in public FDA and regional records.

  9. arsenic trioxide

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Thioredoxin reductase 1, cytoplasmic.

    Target
    Thioredoxin reductase 1, cytoplasmic
    Mechanism
    Thioredoxin reductase 1 inhibitor

  10. atezolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 inhibitor

  11. atosiban

    Genito-urinary system and sex hormones (G02)

    Genito-urinary system and sex hormones (G02) compound in University of Hong's portfolio. Molecular target: Oxytocin receptor.

    Target
    Oxytocin receptor
    Mechanism
    Oxytocin receptor antagonist

  12. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  13. biosimilar

    Development asset linked to University of Hong in public FDA and regional records.

  14. brolucizumab

    Sensory organs (S01)

    Sensory organs (S01) compound in University of Hong's portfolio. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  15. bupivacaine

    Nervous system (N01)

    US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.

    Target
    Sodium channel protein type 4 subunit alpha
    Mechanism
    Sodium channel protein type IV alpha subunit blocker

  16. bupivacaine hydrochloride

    US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.

    Target
    Sodium channel protein type 4 subunit alpha
    Mechanism
    Sodium channel protein type IV alpha subunit blocker

  17. calcium chloride

    US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.

    Mechanism
    Dihydrofolate reductase inhibitor

  18. calfactant

    US regulatory status: approved. Mechanism: Surfactant agent.

    Mechanism
    Surfactant agent

  19. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  20. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  21. chloride

    Development asset linked to University of Hong in public FDA and regional records.

  22. chlorothiazide

    US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.

    Target
    Solute carrier family 12 member 3
    Mechanism
    Thiazide-sensitive sodium-chloride cotransporter inhibitor

  23. cinacalcet

    Systemic hormonal preparations (H05)

    Systemic hormonal preparations (H05) compound in University of Hong's portfolio. Mechanism: Calcium sensing receptor positive allosteric modulator.

    Mechanism
    Calcium sensing receptor positive allosteric modulator

  24. covid-19 vaccine (inactivated, adjuvanted, adsorbed)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in University of Hong's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  25. dapagliflozin

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.

    Target
    Sodium/glucose cotransporter 2
    Mechanism
    Sodium/glucose cotransporter 2 inhibitor

  26. decitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.

    Target
    DNA (cytosine-5)-methyltransferase 1
    Mechanism
    DNA (cytosine-5)-methyltransferase 1 inhibitor

  27. dexamethasone sodium phosphate

    US regulatory status: approved. Molecular target: Glucocorticoid receptor.

    Target
    Glucocorticoid receptor
    Mechanism
    Glucocorticoid receptor agonist

  28. dexmedetomidine

    Nervous system (N05)

    Nervous system (N05) compound in University of Hong's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.

    Mechanism
    Adrenergic receptor alpha-2 agonist

  29. diethylpropion hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.

    Target
    Sodium-dependent dopamine transporter
    Mechanism
    Norepinephrine transporter inhibitor

  30. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in University of Hong's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  31. fluoxetine

    Development asset linked to University of Hong in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.

    Mechanism
    Serotonin transporter inhibitor

  32. fluoxetine hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.

    Target
    Sodium-dependent serotonin transporter
    Mechanism
    Serotonin transporter inhibitor

  33. folate

    Development asset linked to University of Hong in public FDA and regional records.

  34. folic

    Development asset linked to University of Hong in public FDA and regional records.

  35. folic acid

    Various (V04)

    US regulatory status: approved.

  36. gemcitabine

    US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.

    Mechanism
    DNA polymerase (alpha/delta/epsilon) inhibitor

  37. hydrochlorothiazide

    US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.

    Target
    Solute carrier family 12 member 3
    Mechanism
    Thiazide-sensitive sodium-chloride cotransporter inhibitor

  38. inactivated

    Development asset linked to University of Hong in public FDA and regional records.

  39. individual

    Development asset linked to University of Hong in public FDA and regional records.

  43. inhibitor

    Development asset linked to University of Hong in public FDA and regional records.

  44. injection

    Development asset linked to University of Hong in public FDA and regional records.

  45. interferon alfa-2b

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  46. interferon beta-1b

    Antineoplastic and immunomodulating agents (L03)

    US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.

    Target
    Interferon alpha/beta receptor
    Mechanism
    Interferon alpha/beta receptor agonist

  47. intervention

    Development asset linked to University of Hong in public FDA and regional records.

  48. ivabradine

    Cardiovascular system (C01)

    US regulatory status: approved. Molecular target: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4.

    Target
    Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4
    Mechanism
    Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker

  49. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  50. nicotine

    US regulatory status: approved. Molecular target: Neuronal acetylcholine receptor; alpha4/beta2.

    Target
    Neuronal acetylcholine receptor; alpha4/beta2
    Mechanism
    Neuronal acetylcholine receptor; alpha4/beta2 agonist

  51. ointment

    Development asset linked to University of Hong in public FDA and regional records.

  52. paclitaxel

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  53. paracetamol

    Development asset linked to University of Hong in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Anandamide amidohydrolase inhibitor

  54. pembrolizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

  55. pingchan

    Development asset linked to University of Hong in public FDA and regional records.

  56. propofol

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  57. protocol

    Development asset linked to University of Hong in public FDA and regional records.

  58. rivaroxaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Coagulation factor X.

    Target
    Coagulation factor X
    Mechanism
    Coagulation factor X inhibitor

  59. sevelamer

    Various (V03)

    Various (V03) compound in University of Hong's portfolio.

  60. sevelamer hydrochloride

    Various (V03)

    US regulatory status: approved. Molecular target: Phosphate.

    Target
    Phosphate
    Mechanism
    Phosphate sequestering agent

  61. solution

    Development asset linked to University of Hong in public FDA and regional records.

  62. stro-

    Development asset linked to University of Hong in public FDA and regional records.

  63. t-cell

    Development asset linked to University of Hong in public FDA and regional records.

  64. tablet

    Development asset linked to University of Hong in public FDA and regional records.

  65. therapy

    Development asset linked to University of Hong in public FDA and regional records.

  66. traditional

    Development asset linked to University of Hong in public FDA and regional records.

  68. usual

    Development asset linked to University of Hong in public FDA and regional records.

  69. vaccine

    Development asset linked to University of Hong in public FDA and regional records.

  70. valsartan

    US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.

    Target
    Type-1 angiotensin II receptor
    Mechanism
    Type-1 angiotensin II receptor antagonist

  71. vortioxetine

    Nervous system (N06)

    US regulatory status: approved. Mechanism: Serotonin 3a (5-HT3a) receptor antagonist.

    Mechanism
    Serotonin 3a (5-HT3a) receptor antagonist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.